Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Sader, Helio S ^a   Jones, Ronald N ^a   Rossi, Kerri L ^b   Rybak, Michael J ^b  

^a JMI LABORATORIES   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Daptomycin; Macro Etest method; MRSA; Teicoplanin; Vancomycin tolerance

Indexed keywords

DAPTOMYCIN; METICILLIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACCURACY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CONTROLLED STUDY; DILUTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SENSITIVITY AND SPECIFICITY; UNITED STATES; ANTIBIOTIC RESISTANCE; BACTEREMIA; CLINICAL TRIAL; DRUG EFFECT; DRUG TOLERANCE; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DRUG TOLERANCE; HOSPITALS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; UNITED STATES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 73949100864     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp319     Document Type: Article

References (22)

1. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003; 82: 333-9.
2. Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycinintermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
3. Jones RN, Ross JE, Fritsche TR et al. Oxazolidinone susceptibility patterns in 2004: report from the Zyvoxw Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006; 57: 279-87.
4. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycinintermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-6.
5. Rose WE, Leonard SN, Rossi KL et al. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2009; 53: 805-7.
6. Asseray N, Jacqueline C, Le Mabecque V et al. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy. Antimicrob Agents Chemother 2005; 49: 857-9.
7. French GL. Bactericidal agents in the treatment of MRSA infections- the potential role of daptomycin. J Antimicrob Chemother 2006; 58: 1107-17.
8. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665-72.
9. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004; 38: 864-70.
10. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-5.
11. Rybak MJ, Leonard SN, Rossi KL et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46: 2950-4.
12. Wootton M, MacGowan AP, Walsh TR et al. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007; 45: 329-32.
13. Maor Y, Rahav G, Belausov N et al. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J ClinMicrobiol 2007; 45: 1511-4.
14. Walsh TR, Bolmstrom A, Qwarnstrom A et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39: 2439-44.
15. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
16. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006; 50: 2330-6.
17. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
18. Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern Med J 2005; 35 Suppl 2: S136-40.
19. Deresinski S. Vancomycin heteroresistance and methicillinresistant Staphylococcus aureus. J Infect Dis 2009; 199: 605-9.
20. Maor Y, Hagin M, Belausov N et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
21. Leonard SN, Rossi KL, Newton KL et al. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009; 63: 489-92.
22. Yusof A, Engelhardt A, Karlsson A et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptideintermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol 2008; 46: 3042 7.